Global Messenger RNA (mRNA) Vaccines & Therapeutics Market will reach US$ 26.34 Billion by 2028. Messenger Ribonucleic Acid (mRNA) is a term that refers to a single protein-coding gene in the genome that conforms as the basis for protein synthesis in cells. mRNA vaccines and treatments are made in laboratories utilizing mammalian cells and have favorable immunological characteristics. Infection prevention mRNA vaccines, infectious disease treatment mRNA vaccines, customized cancer therapy mRNA vaccines, and standardization of cancer treatment mRNA vaccines are frequent types of vaccinations and therapies. They are injected into the body to activate virus-detecting immunological sensors and cause the cells to generate viral antigen proteins. This improves B- and T-cell responses, which helps the body's immunity.Messenger RNA (mRNA) Vaccines & Therapeutics Market Size, Global Forecast 2023-2028
Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Size will expand at a CAGR of 14.60% from 2022 to 2028:
mRNA vaccines and treatments are generated employing new technologies that are more effective against infections, have higher potency, improved immunogenicity, and are relatively more cost-effective than conventional pharmaceuticals. One of the critical factors propelling the development of the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market is the increased prevalence of medical disorders such as diabetes, TB, cancer, and cardiovascular diseases (CVDs). In addition, the industry also benefits from rising demand for therapeutic drugs and vaccines for Ebola, influenza, HIV, and other viral illnesses.Evolution of the Global Messenger RNA (mRNA) Vaccines & Therapeutics Industry amidst Pandemic:
With the launch and widespread usage of mRNA vaccines and therapies for COVID-19, 2020 marked a watershed moment for mRNA technology platforms. As a result, the combined market valuation of mRNA platforms had increased fast by 2020. The increase in market value reflects expectations that mRNA technology will give far more than the current COVID-19 preventive vaccines. according to the publisher, the Global Messenger RNA (mRNA) Vaccines and Therapeutics Market was valued at US$ 11.63 Billion in 2022.Global Messenger RNA (mRNA) Vaccines & Therapeutics Market: Segmentation Analysis:
By Type, the market is bifurcated into Infection Prevention mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine, and Standardization of Cancer Treatment mRNA Vaccine.By Application, Cancer, Infectious Diseases, and Others are the major segments covered in our report. As per our estimates, Infectious Diseases hold a significant share in the market and are estimated to remain dominant throughout the forecasted period.
By End User, we have studied the market for hospitals, Clinics, Diagnostics Centers, and Others. As per our analysis, clinics and diagnostic centers are gaining traction with the advancement of technology applications. However, hospitals tend to remain dominant throughout the study period.
By Region, North America, Europe, Asia-Pacific, and Rest of the World. During the forecast period, North America is estimated to monopolize the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market. The market in North America is contrived by an increase in demand for COVID-19 mRNA vaccines, major players operating in the US, and an exponential rise in the number of COVID-19 cases in the US.
Key Players:
Pfizer, GlaxoSmithKline, Daiichi Sankyo Company, Limited, Intellia Therapeutics, Moderna Inc, CureVac N.V., Arcturus Therapeutics Holdings, and BioNTech are the prominent companies in the Global Messenger RNA (mRNA) Vaccines & Therapeutics Market examined in our analysis. In addition, we have discussed the competition landscape section of the study, which included an overview, the latest development strategies, and market revenue analysis of the above-mentioned worldwide companies. Surprisingly, the major firms invest in mRNA technologies since they can integrate numerous molecules into a therapeutic drug, which is a huge growth factor.The publisher's latest report “Global Messenger RNA (mRNA) Vaccines & Therapeutics Market, Global Forecast By Type (Infection Prevention mRNA Vaccine, Infectious Disease Treatment mRNA Vaccine, Individualized Cancer Treatment mRNA Vaccine and Standardization of Cancer Treatment mRNA Vaccine), Application (Cancer, Infectious Diseases and Others), End User (Hospital, Clinics, Diagnostics Centers and Others), Region (North America, Europe, Asia-Pacific and Rest of the World), Companies (Pfizer, GlaxoSmithKline, Daiichi Sankyo Company, Limited, Intellia Therapeutics, Moderna Inc, CureVac N.V., Arcturus Therapeutics Holdings, and BioNTech)” provides a detailed analysis of Global Messenger RNA (mRNA) Vaccines & Therapeutics Industry.
Type - The market has been studied from 4 viewpoints:
1. Infection Prevention mRNA Vaccine2. Infectious Disease Treatment mRNA Vaccine
3. Individualized Cancer Treatment mRNA Vaccine
4. Standardization of Cancer Treatment mRNA Vaccine
Application - The market has been studied from 3 viewpoints:
1. Cancer2. Infectious Diseases
3. Others
End Use - The market has been studied from 4 viewpoints:
1. Hospital2. Clinics
3. Diagnostics Centers
4. Others
Region - The market has been studied from 4 viewpoints:
1. North America2. Europe
3. Asia-Pacific
4. Rest of the World
Company Insights:
- Overview
- Recent Development
- Revenue
Key Players:
1. Pfizer2. GlaxoSmithKline's
3. Daiichi Sankyo Company, Limited.
4. Intellia Therapeutics
5. Moderna Inc
6. CureVac N.V.
7. Arcturus Therapeutics Holdings
8. BioNTech
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary
Companies Mentioned
- Pfizer
- GlaxoSmithKline's
- Daiichi Sankyo Company, Limited.
- Intellia Therapeutics
- Moderna Inc
- CureVac N.V.
- Arcturus Therapeutics Holdings
- BioNTech
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...